ANNUAL REPORT FY22 27 Relationship between the remuneration policy and Consolidated Entity performance The Board considers that at this time, evaluation of the Consolidated Entities financial performance using generally accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated Entity is in the pre-clinical phase of drug development. 2022 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees Bonus Other Superannuation Options and performance shares2 $ $ $ $ $ $ Non-Executive Directors John Moore 181,135 - - - 83,698 264,833 Peter Marks 76,275 - - - 41,849 118,124 Rüdiger Weseloh1 82,812 - - - 41,849 124,661 Marcus Frampton 76,633 - - - 41,849 118,482 Christopher Cox 76,633 - - - 41,849 118,482 Ian Dixon 76,577 - - - 177,275 253,852 Executive Employees James Bonnar (CEO) 273,750 - 21,093 27,375 141,928 464,146 Total 843,815 - 21,093 27,375 570,297 1,462,580 1 Rüdiger was remunerated $13,144 for services provided outside of his Director role for R&D consulting. The fees paid to Rüdiger were at market rates. 2. The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and this amount does not represent a cash benefit to the key management personnel. 2021 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees Bonus Other Superannuation Options and performance shares5 $ $ $ $ $ $ Non-Executive Directors John Moore 130,101 - - - 182,564 312,665 Graham Kelly1 5,189 - - 493 191,780 197,462 Peter Marks 49,522 - - - 91,282 140,804 Rüdiger Weseloh3 66,906 - - - 91,282 158,188 Marcus Frampton 51,887 - - - 91,282 143,169 Christopher Cox 51,887 - - - 91,282 143,169 Ian Dixon2 40,800 - - - 149,2054 190,005 Executive Employees James Bonnar (CEO) 277,177 - 18,163 23,948 58,757 378,045 Total 673,469 - 18,163 24,441 947,434 1,663,507 1 Graham Kelly resigned as Non-Executive Director on 8 September 2020. 2. Ian Dixon was appointed as Non-Executive Director on 8 September 2020. 3. Rüdiger Weseloh was remunerated $22,268 for services provided outside of his Director role for R&D consulting. The fees paid were at market rates. 4. The share based payment in relation to performance shares held by related party Altnia Holding Pty Ltd of $80,037 was incorrectly omitted in the 2021 Annual Report. The amount of $149,205 is the restated amount. 5. The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and this amount does not represent a cash benefit to the KMP.
RkJQdWJsaXNoZXIy MjE2NDg3